T-Therapeutics
TCR-CD3 bispecific T-cell engagers for cancer and autoimmune disease
T-Therapeutics (Cambridge, United Kingdom) — tCR-CD3 bispecific T-cell engagers for cancer and autoimmune disease. On November 5, 2026 it announced a $133M Series B, led by Advent Life Sciences and British Business Bank. Oversubscribed. Funds clinical proof-of-concept for two lead programs. Prior: $91M Series A including a $32M extension (late 2025).
Biotech
📍 Cambridge
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is T-Therapeutics going public?
No. T-Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is T-Therapeutics' valuation in 2026?
No confirmed valuation is on record for T-Therapeutics. The roster shows funding and investors where they are public; it does not estimate a mark.
Has T-Therapeutics filed an S-1?
No public S-1 is on file for T-Therapeutics.
Who are T-Therapeutics' investors?
T-Therapeutics' investors include Advent Life Sciences and British Business Bank, Eli Lilly, J&J venture arm, Merck KGaA venture arm, Sanofi Ventures.
How much has T-Therapeutics raised?
T-Therapeutics has raised $224M in total across 1 disclosed round, most recently a Series B of $133M in Nov 2026.
Is T-Therapeutics publicly traded — can you buy T-Therapeutics stock?
No. T-Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for T-Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Last Round
Series B — $133M (Nov 2026) · Lead: Advent Life Sciences and British Business Bank
Fundraising Status
Series B · $133M · this month
privateTotal raised $224M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series B | $133M | Nov 2026 | Advent Life Sciences and British Business Bank | — |
Recent Activity
💰Nov 2026 · Fierce Biotech · funding
Vertical Intelligence — Biotech / Gene Therapy
Biotech / Gene Therapy registry data for T-Therapeutics has not been collected yet — the weekly vertical sweep hasn't reached this company. Check back soon.
Talent Signal
Hiring data for T-Therapeutics has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Investors
Advent Life Sciences and British Business Bank · Eli Lilly · J&J venture arm · Merck KGaA venture arm · Sanofi Ventures
BiotechTCR-CD3 bispecific T-cell engagers
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.